Fundamental Analysis of CENTESSA PHARMACEUTICALS-ADR(NASDAQ:CNTA) stock

Fundamental Rating

Overall CNTA gets a fundamental rating of 2 out of 10. We evaluated CNTA against 587 industry peers in the Biotechnology industry. CNTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CNTA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CNTA has reported negative net income.

In the past year CNTA has reported a negative cash flow from operations.

CNTA had negative earnings in each of the past 5 years.

In the past 5 years CNTA always reported negative operating cash flow.

1.2 Ratios

CNTA has a Return On Assets (-41.94%) which is in line with its industry peers.

CNTA has a Return On Equity (-63.95%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-41.94%
ROE	-63.95%
ROIC	N/A

ROA(3y)-50.38%

ROA(5y)-53.58%

ROE(3y)-68.59%

ROE(5y)-117.32%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CNTA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CNTA has more shares outstanding

CNTA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.58, we must say that CNTA is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of CNTA (1.58) is better than 68.03% of its industry peers.

CNTA has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.32, CNTA is not doing good in the industry: 70.09% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.32
Debt/FCF	N/A
Altman-Z	1.58

ROIC/WACCN/A

WACC8.81%

2.3 Liquidity

CNTA has a Current Ratio of 8.00. This indicates that CNTA is financially healthy and has no problem in meeting its short term obligations.

CNTA has a better Current ratio (8.00) than 72.31% of its industry peers.

CNTA has a Quick Ratio of 8.00. This indicates that CNTA is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of CNTA (8.00) is better than 72.65% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8
Quick Ratio	8

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.03% over the past year.

EPS 1Y (TTM)32.03%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q15.56%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

CNTA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.68% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-17.81%

EPS Next 2Y-9.93%

EPS Next 3Y3.83%

EPS Next 5Y7.68%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CNTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CNTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.93%

EPS Next 3Y3.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CNTA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (5/10/2024, 7:00:01 PM)

8.97

-0.58 (-6.07%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap996.72M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-41.94%
ROE	-63.95%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0.32
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	8
Quick Ratio	8
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)32.03%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-17.81%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CENTESSA PHARMACEUTICALS-ADR (CNTA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens